Q1 Earnings Forecast for XOMA Issued By Leerink Partnrs

XOMA Co. (NASDAQ:XOMA) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for XOMA in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earnings per share of ($0.31) for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million.

Several other research analysts have also recently issued reports on the company. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $104.00 target price on shares of XOMA in a research note on Wednesday.

XOMA Trading Up 0.8 %

NASDAQ XOMA opened at $21.06 on Wednesday. The business’s 50-day moving average price is $24.45 and its two-hundred day moving average price is $27.20. XOMA has a 12 month low of $19.92 and a 12 month high of $35.00. The firm has a market capitalization of $248.15 million, a PE ratio of -6.05 and a beta of 1.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

Insider Activity

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of XOMA. Woodline Partners LP grew its holdings in XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after purchasing an additional 60,927 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 8,522 shares during the last quarter. Barclays PLC grew its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in XOMA in the fourth quarter worth $206,000. Finally, Renaissance Technologies LLC grew its holdings in XOMA by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 7,619 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.